Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus

OBJECTIVE: In a previously reported phase II randomized, placebo‐controlled, interventional trial, we demonstrated that treatment with ustekinumab, an anti–interleukin‐12 (IL‐12)/IL‐23 p40 neutralizing monoclonal antibody, improved global and organ‐specific measures of disease activity in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cesaroni, Matteo, Seridi, Loqmane, Loza, Matthew J., Schreiter, Jessica, Sweet, Kristen, Franks, Carol, Ma, Keying, Orillion, Ashley, Campbell, Kim, M. Gordon, Robert, Branigan, Patrick, Lipsky, Peter, van Vollenhoven, Ronald, Hahn, Bevra H., Tsokos, George C., Chevrier, Marc, Rose, Shawn, Baribaud, Frédéric, Jordan, Jarrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986128/
https://www.ncbi.nlm.nih.gov/pubmed/33010188
http://dx.doi.org/10.1002/art.41547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986128/
https://www.ncbi.nlm.nih.gov/pubmed/33010188
http://dx.doi.org/10.1002/art.41547

Ejemplares similares